Core Insights - Alector is advancing its Alector Brain Carrier (ABC) platform across various therapeutic modalities, including antibodies, enzymes, and siRNA, with significant progress in treatments for Alzheimer's and Parkinson's diseases [1][4][16] - The company reported a cash position of $256.0 million as of December 31, 2025, which is expected to fund operations at least through 2027 [2][18] - Alector's CEO emphasized the unique capabilities of the ABC platform and its potential to translate scientific innovation into clinical assets [3] Financial Performance - Collaboration revenue for Q4 2025 was $6.2 million, a decrease from $54.2 million in Q4 2024, with total annual collaboration revenue dropping to $21.0 million from $100.6 million [13] - Research and development expenses for Q4 2025 were $32.5 million, down from $46.5 million in Q4 2024, with total R&D expenses for the year at $123.1 million compared to $185.9 million in 2024 [14] - General and administrative expenses for Q4 2025 were $13.3 million, a slight decrease from $15.0 million in Q4 2024, with annual G&A expenses at $54.0 million compared to $59.6 million in 2024 [15] Pipeline and Program Updates - Alector is advancing AL137, an ABC-enabled anti-amyloid antibody for Alzheimer's, with an IND application expected in Q4 2026 or Q1 2027 [8] - AL050, an ABC-enabled GCase enzyme replacement therapy for Parkinson's disease, is in preclinical development with an IND application targeted for 2027 [9] - The company is also progressing its ABC-enabled siRNA platform, with AL064 selected as the lead candidate for tau-related therapies [16] Clinical Trials - The PROGRESS-AD Phase 2 trial of nivisnebart (AL101) in early Alzheimer's disease is ongoing, with an independent interim futility analysis expected in the first half of 2026 [1][16]